Mundipharma Archives -

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal

Cidara and Mundipharma prep filings for antifungal rezafungin

https://pharmaphorum.com/news/cidara-and-mundipharma-prep-filings-for-antifungal-rezafungin/

Mundipharma has fleshed out its range of biosimilars by acquiring Tuznue, a version of Roche’s breast cancer blockbuster

New deals extend Mundipharma biosimilar reach

https://pharmaphorum.com/news-market-access/new-deals-extend-mundipharma-biosimilar-reach/

Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor

Mundipharma, Grünenthal accused of kickbacks in Italy

https://pharmaphorum.com/news/mundipharma-grunenthal-italy-opioid/

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU

Mundipharma’s Neulasta biosimilar approved in EU

https://pharmaphorum.com/news/mundipharmas-neulasta-biosimilar-approved-in-eu/

The Mundipharma network of independent pharma companies has appointed Arnaud Breabout as chief financial officer. Breabout was most

Mundipharma appoints former GSK exec as CFO

https://pharmaphorum.com/news/mundipharma-appoints-former-gsk-exec-as-cfo/

Mundipharma, a network of independent pharma companies, has bought Spanish biosimilars development company Cinfa Biotech. The deal will

Mundipharma buys Spanish biosimilars firm Cinfa Biotech

https://pharmaphorum.com/news/mundipharma-buys-spanish-biosimilars-firm-cinfa-biotech/

Mundipharma’s third biosimilar tie-up with Celltrion

Mundipharma to market Herceptin biosimilar in key EU markets

https://pharmaphorum.com/news/mundipharma-market-celltrion-cancer-biosimilar-key-eu-markets/

Drug will be progressed through phase 3 trials in biliary tract cancer.

Mundipharma buys rights to CellAct cancer drug

https://pharmaphorum.com/news/mundipharma-cellact/

Mundipharma